Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 248-742-6 | CAS number: 27939-60-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Vertoliff repeated dose information from a rat oral gavage OECD TG 407 study: NOAEL for systemic effects is 500 mg/kg bw.
Key value for chemical safety assessment
- Toxic effect type:
- dose-dependent
Repeated dose toxicity: via oral route - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEL
- 500 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- For repeated dose toxicity one subacute oral study is available performed with Vertoliff according to OECD guideline 407 in compliance with GLP.
- System:
- other: Increased liver weight
- Organ:
- liver
Additional information
Repeated dose toxicity – Endpoint summary
For Vertoliff a repeated dose toxicity study and a reproscreen study according to OECD TG 407 and OECD TG 421, respectively, are available, which are summarised below and an overall NOAEL of these two studies will be derived.
Vertoliff repeated dose toxicity in the OECD TG 407
Introduction: The 28-day repeated dose toxicity of Vertoliff was tested in an oral gavage rat OECD TG 407 study. Repeated dose toxicity information of Vertoliff was available from an OECD TG 421 and a structural isomer Triplal (Cas no 27939-60-2 one isomer). These data indicated that the maximum high dose should be 750 mg/kg bw based on the irritancy seen at this dose in the stomach.
Method: The test item was dissolved in corn oil and the control group was handled identically as the dose groups but received the vehicle instead of test item formulation. The groups comprised 5 male and 5 female Wistar rats each. The following doses were evaluated: 0, 250, 500 and 750 mg/kg bw. During the period of administration, the animals were observed precisely each day for signs of toxicity. Body weight and food consumption were measured weekly. Haematology and clinical biochemistry parameter were measured. Animals that died were examined macroscopically and at the conclusion of the test, all surviving animals were sacrificed and observed macroscopically. The wet weight of a subset of tissues was taken and a set of organs/tissues was preserved. A full histopathological evaluation of the tissues was performed on high dose and control animals. Any gross lesion macroscopically identified was examined microscopically in all animals.
Results, mortality: There were two mortalities during the treatment phase. In both animals nos. 9 and 12 the cause of morbidity was most likely due to traumatic injury during the gavage procedure. Therefore, all lesions were considered incidental.
Clinical signs: There were clinical signs related to the irritancy of the substance e.g. slight to severe reduced spontaneous activity on some occasions, some in the mid dose and all males and females in the high dose. There were no test item-related clinical signs of systemic toxicity observed during the treatment period in any of the animals. In addition, detailed clinical examinations, functional observation battery (FOB) and ophthalmoscopy examination did not reveal any test item-related effects in any of the treatment groups.
Body weight and food consumption: In males and females, there was no test item-related effect on body weight or food consumption during the treatment period.
Haematology and blood coagulation: No toxicologically relevant effects were observed in test item-treated animals.
Clinical biochemistry: No toxicologically relevant effects were observed in test item-treated animals.
Organs: In the stomach, there was a minor increase of hyperkeratosis on the squamous epithelium in the forestomach in animals at 750 mg/kg bw/day. In addition, in one female at 750 mg/kg bw/day, there was a minimal ulceration in the forestomach associated with forestomach submucosal inflammation and hyperplasia of the squamous epithelium. It is therefore considered that the test item caused a minor irritation at the high dose. Relative liver weights were increased at the high dose in males and females (ca 30%) but without histopathological changes. The magnitude of the change is considered adverse (>20% as the substances seems to exceed the metabolic capacity).
Conclusion: the NOAEL for irritation is based on the clinical signs seen and the local irritation in the stomach at 750 mg/kg bw and is set to 500 mg/kg bw/day. The NOAEL for systemic effects is set to 500 mg/kg bw/day based on increased relative liver weights exceeding the 20% level. Other increased organ weights were seen and were without histopathological changes that indicated an adverse effect.
Vertoliff repeated dose toxicity seen in the Reproscreen toxicity study according to OECD TG 421
A reproduction/ developmental toxicity screening was performed according to OECD TG 421 and GLP.
Method: The substance was administered orally (gavage) to male and female Wistar Han IGS rats at dose levels of 50, 150 and 500 mg/kg bw/day (12 rats/sex/dose level). Concurrent controls (12 rats/sex) were performed with the vehicle (corn oil). Parental animals were exposed 2 weeks prior mating and during mating. Male rats and non-mated female rats were exposed until sacrifice (study day 30). Mated females were dosed from the start of the gestation period (the finding of a sperm positive vaginal smear was considered gestation day 0) up to delivery of the pups. During the lactation period, females were dosed up to sacrifice, after overnight fasting, on day 14 of lactation. The test substance was considered to be homogeneously distributed and to be stable in the gavage liquids under the experimental conditions. Although the concentration of the test substance of the mid-dose groups of the gavage liquids prepared was 14% lower than intended, in general, the concentration of the test substance was close to intended (90-110% of the intended concentration).
Results: For the male and female animals, there were no mortalities observed and no treatment related effects on macroscopic parameters and body weight were observed. Although food consumption was affected in the post-mating period of the male animals in mid- and high dose groups and in pregnant females in the high dose group, this was not considered as an adverse effect of the treatment. In male animals of the high-dose group, the absolute- (+13.6%) and relative (+16.8%) liver weights and the relative kidney weight (+8.0%) were statistically significantly increased as compared to the control animals. Microscopic evaluation revealed a treatment-related increase of accumulation of hyaline droplets in tubular epithelial cells in the outer cortex of the kidneys, accompanied by degenerative changes of these cells in 6/12 high dose males in most cases the hyaline droplets were also present in the lumen of the tubules. Immunohistochemically staining with a monoclonal antibody against alpha 2u revealed that there was insufficient evidence to identify the hyaline droplets as alpha 2 urinary microglobulins. In female animals of the mid- and high-dose groups, the absolute (+9.9% and +24.7%, respectively) and relative (+9.0% and +24.2%, respectively) weights of the liver were statistically significantly increased as compared to the control group. The increased liver weighs are somewhat high (>20%) but in absence of affected biochemistry parameters and histopathology these are considered non-adverse. No toxicological adverse effects on T4 and TSH hormones were observed in male and female parental animals.
In conclusion, systemic effects were observed in the high dose group (500 mg/kg bw/day). Though relative liver weight were slightly above 20%, these were not considered adverse in absence of biochemistry and histopathology changes. A NOAEL of 150 mg/kg bw/ day was therefore derived based on effects on kidney (male) and microscopic effects observed in the kidneys (male). For females the NOAEL was 500 mg/kg bw.
Repeated dose effects of Vertoliff in the OECD TG 407 versus the OECD TG 421
In the table below the Vertoliff repeated dose effects from the OECD TG 407 and 421 are summarised to distinguish between the study report NOAELs and the overall NOAEL for repeated dose toxicity.
Local irritation effects: Irritation in the stomach is seen at the high dose of 750 mg/kg bw in OECD TG 407 but not in the OECD TG 421. The NOAEL for local effects is considered to be 500 mg/kg bw.
Systemic effects: Relative liver weight effects are seen at the high dose. In the OECD TG 407 study these weights increase up to ca 30% in both males and females. In the OECD TG 421 these are slightly lower ca 20% in males and females. In view of these increases at 30% in the OECD TG 407, these are considered adverse despite absence of related biochemistry values or histopathology in the liver and indicate overload of the metabolic pathway. The relative liver weights in the OECD TG 421 are around 20% and considered adaptive and not adverse.
Kidney: Some hyaline droplets related to alpha-2u globulin were seen in the OECD TG 407 in the control and high dose and therefore not considered adverse. In the OECD TG 421 these droplets were seen in the males in the high dose only but alpha-2u globulin could not be confirmed with the staining applied. The difference on the frequency and type of these droplets between the two studies makes the adversity questionable and were not taken into consideration for the overall NOAEL for repeated dose toxicity.
Conclusion: The NOAEL for local irritation is set at 500 mg/kg bw/day based on clinical signs and irritant effects in the stomach at 750 mg/kg bw. For systemic effects most organ weights were not considered adverse due to absence of statistical significance, absence of dose relation and/or absence of histopathological findings. The NOAEL for systemic effects is based on the OECD TG 407 and set to 500 mg/kg bw/day based on increased relative liver weight up to ca 30% both in males and females indicating overloading the metabolic pathway.
Vertoliff | OECD TG 407 | OECD TG 421 |
Strain of rat | Wistar | Wistar |
| Key information | Key information |
Doses | 250/500/750 | 50/150/500 |
Effects |
|
|
Clinical signs and functional tests | No treatment related effects | No treatment related effects |
Heamatology and blood coagulation | No treatment related effects | No treatment related effects |
Clinical biochemistry | No treatment related effects | No treatment related effects |
Organ |
|
|
Stomach histopathology | Irritation effects in stomach are seen in HD | No treatment related effects |
Local NOAEL | 500 mg/kg bw | 500 mg/kg bw |
Relative liver weights | Males and females, HD = +Ca 30% | Males +17 and +24% in females in HD |
Liver histopathology | No treatment related effects | No treatment related effects |
Relative kidney weights | No treatment related effects | Males only, HD = +8% (males only) |
Kidney histopathology | All doses, in males: Hyaline droplets were confirmed to be alpha 2 u globulin present in control and high dose | In males: Hyaline droplets alpha-2uglobulin was not confirmed |
Systemic NOAEL in report | 750 mg/kg bw based on absence of histopathology effects in liver and other organs | 150 mg/kg bw based on male kidney effects at 500 mg/kg bw |
Overall assessment of systemic NOAEL mg/kg bw | 500 based on increased relative liver weight > 20-30% (males and females) | 500 relative liver weight increase is ca 20% and not considered adverse (males and females) |
HD: High dose
Justification for classification or non-classification
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.